205 related articles for article (PubMed ID: 21221710)
1. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.
Davidson D; Coulombe Y; Martinez-Marignac VL; Amrein L; Grenier J; Hodkinson K; Masson JY; Aloyz R; Panasci L
Invest New Drugs; 2012 Jun; 30(3):1248-56. PubMed ID: 21221710
[TBL] [Abstract][Full Text] [Related]
2. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.
Davidson D; Grenier J; Martinez-Marignac V; Amrein L; Shawi M; Tokars M; Aloyz R; Panasci L
Invest New Drugs; 2012 Aug; 30(4):1736-42. PubMed ID: 21567185
[TBL] [Abstract][Full Text] [Related]
3. DNA-dependent protein kinase: effect on DSB repair, G2/M checkpoint and mode of cell death in NSCLC cell lines.
Sak A; Groneberg M; Stuschke M
Int J Radiat Biol; 2019 Sep; 95(9):1205-1219. PubMed ID: 31287365
[No Abstract] [Full Text] [Related]
4. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.
Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L
J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
6. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Davidson D; Wang Y; Aloyz R; Panasci L
Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
8. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
Gustafsson AS; Abramenkovs A; Stenerlöw B
Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
10. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
11. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
Paillas S; Boissière F; Bibeau F; Denouel A; Mollevi C; Causse A; Denis V; Vezzio-Vié N; Marzi L; Cortijo C; Ait-Arsa I; Askari N; Pourquier P; Martineau P; Del Rio M; Gongora C
Cancer Res; 2011 Feb; 71(3):1041-9. PubMed ID: 21159664
[TBL] [Abstract][Full Text] [Related]
12. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
13. TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma.
Cabal-Hierro L; O'Dwyer PJ
Mol Cancer Res; 2017 Apr; 15(4):395-404. PubMed ID: 28087739
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Plasencia C; Abad A; Martinez-Balibrea E; Taron M
Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710
[TBL] [Abstract][Full Text] [Related]
16. Activation of DNA damage repair pathways in response to nitrogen mustard-induced DNA damage and toxicity in skin keratinocytes.
Inturi S; Tewari-Singh N; Agarwal C; White CW; Agarwal R
Mutat Res; 2014; 763-764():53-63. PubMed ID: 24732344
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
18. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
19. DNA-PK inhibition causes a low level of H2AX phosphorylation and homologous recombination repair in Medaka (Oryzias latipes) cells.
Urushihara Y; Kobayashi J; Matsumoto Y; Komatsu K; Oda S; Mitani H
Biochem Biophys Res Commun; 2012 Dec; 429(3-4):131-6. PubMed ID: 23142596
[TBL] [Abstract][Full Text] [Related]
20. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.
Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G
Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
